Purple Flowers
Summary
Reflections on FDA Draft Guidance on Bayesian Methods in Trials-Protecting Scientific Integrity and Evidentiary Standards. Evans SR(1)(2), Fleming TR(3), Janes H(4), Dodd LE(5). Author information: (1)Biostatistics Center, George Washington University, Washington, DC. (2)Department of Biostatistics and Bioinformatics, George Washington University, Washington, DC. (3)Department of Biostatistics, University of Washington, Seattle. (4)Fred Hutchinson Cancer Center, Seattle, Washington. (5)Clinical
Content
# Purple Flowers
*Published: 2026 May 19*
Reflections on FDA Draft Guidance on Bayesian Methods in Trials-Protecting Scientific Integrity and Evidentiary Standards. Evans SR(1)(2), Fleming TR(3), Janes H(4), Dodd LE(5). Author information: (1)Biostatistics Center, George Washington University, Washington, DC. (2)Department of Biostatistics and Bioinformatics, George Washington University, Washington, DC. (3)Department of Biostatistics, University of Washington, Seattle. (4)Fred Hutchinson Cancer Center, Seattle, Washington. (5)Clinical Trials Research and Statistics Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. Plain Language Summary: This Perspective discusses the use of bayesian methods in clinical trials and the importance of having US Food and Drug Administration (FDA) guidance that provides substantive insights about the methods’ proper role. DOI: 10.1001/jama.2026.4175
DOI: 10.1001/jama.2026.2239